Avata Biosciences is thrilled to announce a significant funding milestone, having raised an impressive $110 million in its latest investment round. Formerly known as Sapient Therapeutics Ltd., Avata is a clinical-stage biopharmaceutical company dedicated to transforming the treatment landscape for patients afflicted by neurological diseases. With a pioneering approach that leverages synthetic cannabinoids and an innovative formulation process, Avata aims to broaden the reach of therapies to larger patient populations who currently face limited treatment options. The recent funding will be strategically directed towards advancing Avata's clinical trials, bolstering research and development efforts, and accelerating the pathway to FDA approval for its proprietary therapeutics. This injection of capital underscores investor confidence in Avata's vision to not only enhance the quality of life for individuals suffering from neurological conditions but also to establish a new paradigm in patient care. As the company forges ahead, it remains committed to advancing scientific discovery and delivering groundbreaking solutions that harness the potential of cannabinoids in managing complex neurological disorders. With this pivotal funding round, Avata Biosciences is poised to make significant strides in its mission, and we look forward to sharing more about our progress in the months to come.
Avata Biosciences Secures $110 Million in Funding to Revolutionize Treatment for Neurological Diseases
Get the full Avata Biosciences company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
EVOKEN GLOBAL
We are the a parent company to specialized high-end marketing branches that caters to VIP private events. Our expertise lies in databased SM marketing strategies with a strong focus on sustainability. Connect with us to learn more about how we can elevate your brand and create exclusive experiences for your VIP clientele and audience.
$300.0M Series b
today
Strand Intelligence
CRN Channel Cloud Excellence Finalist 2025 ? Strand is a cybersecurity startup building the next generation of incident response. Our AI-powered DFIR platform automates evidence gathering, investigation, remediation, timeline construction and reporting, reducing operational effort by over 90 percent. Built with real-world responders, purpose built for the mid-market MSPs and MSSPs. We help our clients respond to breaches faster, cheaper and without outsourcing. If you manage security incidents or clients experiencing breaches, we want to hear from you.
$1.3M Seed
today
ZapScale
ZapScale is the easiest Customer Success Platform for B2B SaaS companies to help them reduce churn, improve retention and increase upsell.
$2.5M Seed
today
Viken Detection
Viken Detection provides enabling security imaging and material identification solutions that help law enforcement and safety inspection professionals keep the public safe from drug trafficking, terrorism and other hazardous threats. The company鈥檚 innovative products, the Osprey-UVX (vehicle scanner), the Nighthawk-HBI (handled imager) and Pb200ie (lead-paint analyzer), are the recognized leaders in their markets. Viken Detection is headquartered just west of Boston, Massachusetts.
$20.0M Unknown
today
TrustLab
TrustLab helps enterprises maximize the reliability and ROI of AI systems with smarter monitoring of decisions, labeling, and licensed content detection. With a founding team with over 40 years of collective Digital Trust experience at companies like Google, YouTube, Reddit and TikTok, Trust Lab is the trusted third-party solution for detecting and mitigating critical trust & safety threats. --------------------------------------------------------------------------------- **Join us if you or someone you know is interested in developing AI Trust technology: https://www.trustlab.com/careers **Reach out if you or your company is experiencing challenges with AI Trust: https://www.trustlab.com/contact
$15.0M Series a
today